Lung Therapeutics, Inc.
Nearby businesses
Old Fredericksburg Road
78704
S Capital of Texas Highway
S Capital of Texas Highway
3755 S. Capital of Texas Highway #210
S. Capital of Texas Highway
West William Cannon Drive
4029 South Capital of Texas Highway, Suite 110
West Gate Boulevard
Lamar Boulevard
Via Fortuna
S Lamar Boulevard
Via Fortuna
S Lamar Boulevard
Lung Therapeutics, Inc. is a pharmaceutical company targeting niche, orphan drug indications for lun
is a pharmaceutical company targeting niche, orphan drug indications for lung injury and disease, with an emphasis on fibrosis. Current efforts are focused on a severe complication of pneumonia, called loculated pleural effusion, a debilitating condition where fluid has built up in the chest cavity surrounding the lungs and fibrinous scar tissue in the pleural cavity blocks fluid drainage. Our fir

Happy World Health Day!!


It's great to have new team members. Welcome Sydney Kruger to the Lung team!

World Pneumonia Day - Let's raise awareness, promote interventions and generate action.


Timeline photos
Please join us for the second annual Interstitial Lung Disease (ILD) Day! For more information and resources about ILD, visit www.ILDDay.org.

September is Pulmonary Fibrosis Awareness Month

One week away until the 6th Annual IPF Summit in Boston. Brian Windsor will be speaking on day 2 of the summit (8/31):
• 9:45 am Divulging the Clinical Development of LTI-03 in IPF
Synopsis
- Assessing the "dual threat" of LTI-03: inhibition of the profibrotic process and lung regenerative effects
- Uncovering how biomarkers could be sues to reveal these properties
• 11:00 am Panel Discussion: Reflecting on the Progress & Lessons Learned in IPF Clinical Drug Development - Where Will the IPF Road lead us Next?
Panel Discussion group includes the following:
- Peter Smith, Vice President - Product Development, United Therapeutics
- Brian Windsor, Chief Executive Officer, Lung Therapeutics
- Eric White, Senior Clinical Program Lead, Boehringer Ingelheim

Lung Therapeutics honors those suffering with lung cancer.

The Lung Therapeutics Team is looking forward to . We hope to see you there!
starts today! We're excited to safely reconnect in San Francisco after 2 years!

Lung Therapeutics is growing. Meet our new members.

Happy World Health Day from Lung Therapeutics.

Lung Therapeutics Announces Successful Completion of Phase 1a Clinical Trial of LTI-03 in Healthy Volunteers
Lung Therapeutics Announces Successful Completion of Phase 1a Clinical Trial of LTI-03 in Healthy Volunteers Lung Therapeutics' pioneering compound for the treatment of idiopathic pulmonary fibrosis (IPF), LTI-03, has completed a Phase 1a clinical trial.

Timeline photos

Lung Therapeutics, Inc. updated their business hours.

Lung Therapeutics, Inc. updated their phone number.

Lung Therapeutics, Inc. updated their address.

Lung Therapeutics breathes easy with $14M Series B | FierceBiotech
Lung Therapeutics breathes easy with $14M Series B | FierceBiotech Texas startup Lung Therapeutics has got off a $14.3 million Series B round as it eyes the cash boost for its trials in fibrosis, lung injury and disease.

Lung Therapeutics, Inc. Doses First Patient in Phase 1 Clinical Trial of LTI-01 in Australia and New Zealand
Lung Therapeutics, Inc. Doses First Patient in Phase 1 Clinical Trial of LTI-01 in Australia and New Zealand AUSTIN, Texas, March 14, 2017 /PRNewswire/ -- Lung Therapeutics, Inc., a clinical stage pharmaceutical company...

Lung Therapeutics, Inc.
Over 25 years of research has gone into our lung treatment solutions. At Lung Therapeutics, we won't stop until we have the answer.
Lung Therapeutics, Inc. Lung Therapeutics, Inc. is a pharmaceutical company targeting niche, orphan drug indications for lung injury and disease, with an emphasis on fibrosis.
Lung Therapeutics, Inc. Chief Scientific Officer Dr. Steven Idell Receives NIH Grant for Phase...
More great news from Lung Therapeutics with NIH funding for Phase 1A/1B Clinical Trial: http://www.lungtx.com/lung-therapeutics-inc-chief-scientific-officer-dr-steven-idell-receives-nih-grant-phase-1a1b-0
Lung Therapeutics, Inc. Chief Scientific Officer Dr. Steven Idell Receives NIH Grant for Phase... Lung Therapeutics, Inc. Chief Scientific Officer Dr. Steven Idell Receives NIH Grant for Phase 1A/1B Clinical Trial of Drug Candidate LTI-01

Untitled album
Click here to claim your Sponsored Listing.
Category
Contact the business
Telephone
Website
Address
3801 S. Capital Of Texas Highway, Suite 330
Austin, TX
78704
Opening Hours
Monday | 9am - 5pm |
Tuesday | 9am - 5pm |
Wednesday | 9am - 5pm |
Thursday | 9am - 5pm |
Friday | 9am - 5pm |
600 Congress Avenue
Austin, 78701
We are dedicated to enhancing quality and best practices within the h**p industry by supplying innov
1708 Timber Ridge Road
Austin
Nanotize Solutions provides innovative and environmentally responsible molecular technologies to mee
Austin, 78717
Everlum is a Rare Disease Lab as a Service. We believe that everyone deserves a cure no matter how b
624 Headway Circle
Austin, 78754
DiFusion Technologies is a Biotechnology company based in Austin, Texas. We have developed the new Z
5900 Balcones Drive
Austin, 78731
We provide lab and medical supplies to service Houston local community.
PO. Box5
Austin, 30183
*Repair and maintain medical equipment *Setting up laboratories for research institutes and start up
Austin, 78749
Focusing on modulating the extremes of amino acid metabolism, we use novel engineered human enzymes
1108 Lavaca Street, Suite 110/329
Austin, 78701
Angstrom Massively Parallel Diagnostic: Population-Scale Molecular Diagnostic. Unprecedented Through
Metaverse
Austin, 78754
Prophase Biostudios is a 501(c)3 non-profit community biotechnology lab based out of Austin, TX OUR
5217 Winnebago Lane
Austin, 78744
XBiotech is a fully integrated biopharmaceutical that uses proprietary technology to create True Hum
5511 Meadow Crst
Austin, 78744
Fight Free Radicals like never before with this Super Antioxidant
Austin, 78735
Big Fin Scientific creates smart, rugged, digital equipment for Fish Science.